Share price "drifts" downwards?
Only due to shorts
Share price "drifts" downwards?
Only due to shorts shorting and instilling fear into new or weak/kneed investors.
Nader "over-promises". Absolutely not. He has never "promised" anything. Regardless what you think of him, he ain't that dumb, Come On Man! He is over-optimistic about timelines, which are of course out of his control. And some timelines may have been missed, due to fishy influences, who knows.
The bottom line is yes we are due for results, but not overdue to the point of concern. And I certainly agree that the silence is "probably" an indicator of good news, and we have generally always had confidence in s/c data be good or great or better.
I remain with being 4% doubtful, because I don't trust any gov't agency, including the FDA. My sister, a pharma lobbyist says "no way, the FDA is not in the least corrupt". Hmm.
As delays extend, it appears some investors are entering the "grey area" as to whether the FDA may be influenced to delay or deny leronlimab. I say there's a 4% to 8% chance of yes. However, that is the only issue that concerns me, not competition nor our s/c trial data results.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Top 5 Most Recently Viewed Articles
Investors Can Take Control in Outset Medical Securities Case Investors seeking justice now have a valuable opportunity to take the lead in a class action lawsuit against Outset Medical, Inc. (NASDAQ: OM). This legal effort arises from claims suggesting that the company may not have been fully transparent about its product marketing and operational practices. Understanding...
Continue Reading
Insights into IDEXX Laboratories Option Trading In recent times, there has been a notable bearish sentiment among major investors regarding IDEXX Laboratories. Taking a closer look at the trading activities surrounding this stock, our attention shifts towards its options market dynamics. Recent Trading Patterns Analyzing the options history for IDEXX Laboratories (NASDAQ:...
Continue Reading
Key Companies Reporting Earnings Soon As investors gear up for a busy earnings week, a variety of companies are set to disclose their quarterly results. These reports often provide valuable insights into business performance and market trends. Companies Scheduled to Report Before Market Opens So-Young International Inc (NASDAQ: SY) So-Young is anticipated to announce its...
Continue Reading
Welcome to Intelligent Alpha and AI-Driven Investments In today's fast-paced investment world, Doug Clinton, co-founder and Managing Partner at Deepwater Asset Management, has introduced Intelligent Alpha, a groundbreaking investment firm focused on utilizing the power of artificial intelligence. This unique firm distinguishes itself by having an investment committee that...
Continue Reading
Class Action Lawsuit Against Lineage, Inc. In the financial landscape, every investor hopes to see growth in their investments. However, recent developments with Lineage, Inc. have prompted concern among shareholders. It has come to light that some investors may have sustained losses due to alleged securities fraud surrounding the company's performance. As a result, legal...
Continue Reading